Welcome to our dedicated page for Iovance Biotherp SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on tumor infiltrating lymphocyte (TIL) cell therapies for cancer. These documents offer detailed insight into the company’s financial condition, capital structure, product commercialization, and clinical and regulatory activities.
Iovance’s current reports on Form 8-K, for example, describe quarterly financial results, updates on clinical and commercial progress for Amtagvi and Proleukin, corporate presentations used at healthcare conferences, and material agreements such as an amended and restated open market sale agreement that enables at-the-market offerings of common stock. Other 8-K filings outline executive leadership changes and report press releases related to regulatory milestones, including the approval of Amtagvi in Canada for advanced melanoma after anti-PD-1 and targeted therapy.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points, helping readers quickly understand the significance of each document without parsing every technical detail. Real-time updates from the EDGAR system ensure that new filings, such as earnings-related 8-Ks, registration statements, or material financing agreements, appear promptly.
Users can also review filings that touch on equity compensation plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4), which shed light on how Iovance uses stock-based incentives. Together, the full-text filings and AI-generated explanations offer a structured view of how Iovance reports its operations, risk factors, and strategic decisions to regulators and investors.
Iovance Biotherapeutics, Inc. filed an 8-K reporting written and soliciting communications under several securities rules and that it has engaged Jefferies to use commercially reasonable efforts to sell the company’s common shares from time to time under customary trading parameters. The filing references pre-commencement and solicitation rules and states the communication is dated
Iovance Biotherapeutics, Inc. filed a prospectus supplement to sell up to $350.0 million of common stock through an amended at-the-market sales agreement with Jefferies LLC. The agreement replaces the prior June 16, 2023 arrangement and allows sales from time to time, with Jefferies acting as agent and receiving up to 3% of gross proceeds. The company noted its common stock traded at $2.60 per share on August 19, 2025, and estimated up to 476.5 million shares outstanding assuming sale of 134.6 million shares at $2.60. Proceeds are intended to fund the commercial launch of Amtagvi, ongoing and planned clinical trials including IOV-LUN-202 and TILVANCE-301, pipeline development, and general corporate purposes. The prospectus highlights dilution risks, potential market price volatility from resale, indemnification to Jefferies, and forward-looking risks related to clinical, regulatory, manufacturing and financing uncertainties.
Iovance Biotherapeutics reported that Health Canada has approved its therapy Amtagvi (lifileucel) for patients with advanced melanoma who have already received anti-PD-1 and targeted therapies. This gives Canadian patients a new treatment option after other standard treatments have failed. The company shared this news through a press release, which is attached as an exhibit to the report.
Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics (IOVA), reported equity awards dated 08/06/2025. The Form 4 discloses a grant of 300,000 stock options with a $2.58 exercise price and an expiration date listed as 08/06/2035, and 150,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock. Both awards are held directly following the reported transactions. The awards vest only if the reporting person remains employed: one-third vests on the one-year anniversary of the grant and the remaining two-thirds vest in eight equal quarterly installments over the following two years. The form is signed by Corleen Roche on 08/08/2025.
Iovance Biotherapeutics (IOVA) filed an initial Form 3 reporting that Corleen Roche joined the company as Chief Financial Officer on
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) filed a Form 8-K announcing the recruitment of Corleen Roche as Chief Financial Officer, effective August 6, 2025.
The Executive Employment Agreement, signed July 7, 2025, replaces current Principal Financial Officer Matthew W. Rosinack. Roche will receive an annual base salary of $600,000, a $50,000 one-time sign-on bonus, and is eligible for an annual discretionary bonus up to 45 % of salary.
Equity incentives under the 2018 Equity Incentive Plan comprise (i) an option to purchase 300,000 shares at the closing price on the effective date, vesting one-third after 12 months and quarterly thereafter, and (ii) 150,000 restricted stock units with identical vesting cadence. Unvested awards forfeit upon termination except where severance conditions are met.
Severance terms for a termination without cause include: (1) salary continuation for 12 months, (2) pro-rated bonus, (3) immediate vesting of unvested equity, and (4) continuation of applicable benefits. Enhanced protection applies upon a change-of-control event.
Professional background: Roche, 59, has served as CFO of CG Oncology (2024-present), Immunome (2021-2023), and Biogen U.S. (2019-2021), following senior finance roles at Sandoz and Wyeth. She began her career at PwC and holds a B.A. in Accountancy from Villanova University.
The Company issued a press release (Exhibit 99.1) on July 15, 2025 to publicly announce the appointment.
FAQ
What is the current stock price of Iovance Biotherp (IOVA)?
What is the market cap of Iovance Biotherp (IOVA)?
